Synonym
Methallenestril, Ercostrol, Novestrine, Vallestril
IUPAC/Chemical Name
2-Naphthalenepropanoic acid, beta-ethyl-6-methoxy-alpha,alpha-dimethyl- (9CI)
InChi Key
KHLJKRBMZVNZOC-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H22O3/c1-5-16(18(2,3)17(19)20)14-7-6-13-11-15(21-4)9-8-12(13)10-14/h6-11,16H,5H2,1-4H3,(H,19,20)
SMILES Code
O=C(O)C(C)(C)C(CC)C1=CC=C2C=C(OC)C=CC2=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
286.37
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: STROUP PE. Suppression of lactation with methallenestril. Obstet Gynecol. 1958 Feb;11(2):226-9. PubMed PMID: 13504662.
2: GOLDFARB AF, MASSELL G, NAPP EE. The parenteral use of methallenestril for the suppression of lactation; a new approach. West J Surg Obstet Gynecol. 1956 Sep;64(9):492-6. PubMed PMID: 13361224.
3: Herbai G, Ljunghall S. Normalization of hypercalcaemia of primary hyperparathyroidism by treatment with methallenestril, a synthetic oestrogen with low oestrogenicity. Urol Int. 1983;38(6):371-3. PubMed PMID: 6659184.
4: SCHNEEBERG NG, PERCZEK L, NODINE JH, PERLOFF WH. Methallenestril, a new synthetic estrogen. J Am Med Assoc. 1956 Jul 14;161(11):1062-7. PubMed PMID: 13331763.
5: GOLDFARB AF, NAPP EE. Use of methallenestril (vallestril) in control of menopausal symptoms. J Am Med Assoc. 1956 Jun 16;161(7):616-8. PubMed PMID: 13318975.
6: Herbai G, Ljunghall S. Lipid-lowering effects of two synthetic oestrogen derivatives with weak genital oestrogen properties. Ups J Med Sci. 1985;90(1):67-72. PubMed PMID: 4002442.
7: Arvidson NG, Terenius L. Oestrogens and anti-oestrogens show dissociation between early uterine vascular responses and uterotrophic effects in mice. Acta Endocrinol (Copenh). 1982 Jun;100(2):290-4. PubMed PMID: 7202317.
8: PARAISO AQ, GREENWALD L. Our experience with vallestril in the puerperium. Md State Med J. 1955 Jul;4(7):408-10. PubMed PMID: 13243940.
9: STURNICK MI, GARGILL SL. Clinical assay of a new synthetic estrogen: vallestril. N Engl J Med. 1952 Nov 27;247(22):829-34. PubMed PMID: 13002625.
10: FURUYA H, DEGUCHI K, SHIMA M. Experimental and clinical studies on a new synthetic estrogen, an allenolic acid derivative, vallestril. Am J Obstet Gynecol. 1957 Sep;74(3):635-50. PubMed PMID: 13458265.
11: THOMMEN DH. [The use of vallestril in inhibition and suppression of lactation]. Praxis. 1959 Oct 29;48:1013-5. French. PubMed PMID: 13838053.
12: FURUYA H, DEGUCHI K, SHIMA M. Clinical evaluation of a new synthetic estrogen, Vallestril. J Jpn Obstet Gynecol Soc. 1954 Oct;1(4):373-92. PubMed PMID: 13252292.
